Melanoma antigen gene A3 (MAGE‐A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. In this study, for the first time, we performed immunohistochemical analysis to evaluate the expression of MAGE‐A3 in 153 prostate tissue samples including prostate cancer (PCa), benign prostatic hyperplasia (BPH), and high‐grade prostatic intraepithelial neoplasia (HPIN). Increased both nuclear and cytoplasmic expression of MAGE‐A3 was significantly found in PCa tissues compared with both HPIN and BPH tissues (nuclear expression at p = 0.011, and cytoplasmic expression at p = 0.034; for both comparisons p < 0.0001, respectively). A significant correlation was observed between higher nuclear and cytoplasmic expressions of MAGE‐A3 with Gleason score (p < 0.0001 and 0.006, respectively). Increased expression of MAGE‐A3 was associated with shorter biochemical recurrence‐free survival (BCR‐FS) and disease‐free survival (DFS) of patients (p = 0.042 and = 0.0001, respectively). In multivariate analysis, nuclear expression of MAGE‐A3 and Gleason score (≤7 vs >7) was independent predictors of the DFS (both; p = 0.019). Nuclear expression of MAGE‐A3 was also significantly related to BCR‐FS (p = 0.015). MAGE‐A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa.

中文翻译：

---

MAGE-A3的核过表达水平可预测前列腺癌患者的预后不良

黑色素瘤抗原基因A3（MAGE-A3）是最具免疫原性的癌症睾丸抗原之一，在各种类型的癌症中都很常见。在本研究中，我们首次进行了免疫组织化学分析，以评估MAGE-A3在153个前列腺组织样本中的表达，包括前列腺癌（PCa），良性前列腺增生（BPH）和高级前列腺上皮内瘤变（HPIN） 。与HPIN和BPH组织相比，在PCa组织中MAGE-A3的核和细胞质表达均显着增加（p = 0.011的核表达和p = 0.034的胞质表达;两个比较的p均<0.0001）。观察到MAGE-A3的较高的核和细胞质表达与格里森评分之间存在显着相关性（分别为p <0.0001和0.006）。MAGE-A3的表达增加与患者较短的无生化复发（BCR-FS）和无病生存（DFS）有关（分别为p = 0.042和= 0.0001）。在多变量分析中，MAGE-A3的核表达和格里森评分（≤7比> 7）是DFS的独立预测因子（两者； p = 0.019）。MAGE-A3的核表达也与BCR-FS显着相关（p = 0.015）。MAGE-A3可作为PCa患者预后不良的预测指标和疫苗免疫疗法的一种选择。MAGE-A3的核表达也与BCR-FS显着相关（p = 0.015）。MAGE-A3可作为PCa患者预后不良的预测指标和疫苗免疫疗法的一种选择。MAGE-A3的核表达也与BCR-FS显着相关（p = 0.015）。MAGE-A3可作为PCa患者预后不良的预测指标和疫苗免疫疗法的一种选择。